News
OncClub
All Oncology News
Clinical Trials in Focus
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Shorts
Conferences
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
More
Partners
Publications
All Publications
Supplements
Resources
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Scout
My Account
Scout
News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe
AI for Oncology
Biosimilars
Brain Cancer
Breast Cancer
HER2+ Breast Cancer
CAR T-Cell Therapy
Disparities in Cancer Care
Gastrointestinal Cancer
Pancreatic Cancer
Hepatocellular Carcinoma
Gastric Cancer
Colorectal Cancer
Genitourinary Cancers
Urothelial Cancer
Prostate Cancer
Global Oncology
Graft-vs-Host Disease
Gynecologic Oncology
Ovarian Cancer
Head & Neck Cancers
Hematologic Oncology
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Myeloproliferative Neoplasms
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Choose Specialty
Spotlight -
The OncLive Insider app is live!
|
CME Opportunities
Advertisement
Andrea Merrill, MD
Advertisement
Articles by Andrea Merrill, MD
Patients Are a Virtue
By
Andrea Merrill, MD
December 5th 2016
It is 4:45 am on a Saturday in June.
Advertisement
Latest Updated Articles
Patients Are a Virtue
December 5th 2016
Advertisement
Advertisement
Trending on OncLive
1
Pumitamig Plus Chemo Demonstrates Encouraging Efficacy in Frontline NSCLC
2
Experts Weigh In on Some of the Most Impactful Data in Melanoma From ASCO 2026
3
Oral Administration Afforded by CDK2 Inhibitors May Ease the Price of Admission in Platinum-Resistant Ovarian Cancer
4
A global, randomized, double-blinded, Phase 3 trial of vorasidenib vs placebo in patients with grade 2 glioma with an IDH1/2 mutation (INDIGO): updated efficacy and safety
5
Lutetium Lu 177 Vipivotide Tetraxetan Provides rPFS Benefit in mHSPC Regardless of Disease Volume or De Novo/Recurrent Status